XFOR vs QNBC Comparison

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

QNB Corp is a bank holding company based in the United States. It operates through its wholly-owned subsidiary, which engages in the general commercial banking business and offers a full range of banking services to its customers. Its business activities involve attracting deposits and using funds in making commercial loans, residential mortgage loans, consumer loans, and purchasing investment securities. The loan portfolio includes commercial loans, such as commercial and industrial, construction, and loans secured by commercial real estate and residential real estate, and retail loans, including home equity loans and lines, and consumer loans. It generates revenue from net interest income.